Abstract
Introduction: leprosy is a chronic infection caused by Mycobacterium leprae, with a predilection for skin and peripheral nerves. Brazil ranks second worldwide in the number of cases, with a proportional increase in multibacillary forms, indicating delayed diagnoses. Objective: to report a case of virchowian leprosy with type 2 lepra reaction and late diagnosis, highlighting the importance of early clinical suspicion and professional training. Case description: a 74-year old man presented with asthenia, edema, weakness, and paresthesias for five years. He had four hospital admissions in 2024 without a conclusive diagnosis. Progressed with fever and ulcerated nodular lesions. Physical examination showed facial infiltration, madarosis, ichthyosis, gynecomastia, and anesthetic skin lesions. Neurological exam revealed claw hands and foot drop. Skin biopsy revealed xanthomatous histiocytes and a bacilloscopic index of 4+/5+, confirming multibacillary virchowian leprosy associated with necrotizing erythema nodosum leprosum (ENL). Corticosteroid therapy was initiated with clinical improvement, and the patient was referred for multidrug therapy and contact tracing. Discussion: despite presenting typical signs, the diagnosis occurred five years after symptom onset, resulting in physical and psychosocial sequelae. Underdiagnosis reflects limited clinical suspicion and systemic failures. Tools such as the Leprosy Suspicion Questionnaire can aid in early detection. Final considerations: this case highlights the consequences of delayed diagnosis and reinforces the need for healthcare professional training and early screening strategies to prevent disabilities and reduce disease transmission.
References
1. Britton WJ, Lockwood DN. Leprosy. Lancet. 2004;363(9416):1209-19. doi: https://doi.org/10.1016/S0140-6736(04)15952-7.
2. Araújo MG. Hanseníase no Brasil. Rev Soc Bras Med Trop. 2003;36(3):373-43. doi: https://doi.org/10.1590/S0037-86822003000300010.
3. Ministério da Saúde (BR). Boletim Epidemiológico. Hanseníase 2024. Brasília: Ministério da Saúde/Secretaria de Vigilância em Saúde e Ambiente; Jan 2024. Número Especial. [citado em 25 jul. 2025]. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/especiais/2024/be_hansen2024_19jan_final.pdf.
4. World Health Organization. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy. New Delhi: WHO; c2018. [cited 2025 July 25]. Available from: https://www.who.int/publications/i/item/9789290226383.
5. Ministério da Saúde (BR). Guia prático sobre a hanseníase. Brasília: Ministério da Saúde; 2017. [citado em 08 jul. 2025]. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/guia_pratico_hanseniase.pdf.
6. Ministério da Saúde (BR). Protocolo Clínico e Diretrizes Terapêuticas da Hanseníase. Brasília: Ministério da Saúde; 2022. [citado em 25 maio 2025]. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/protocolo_clinico_diretrizes_terapeuticas_hanseniase.pdf.
7. Ribeirão Preto. Secretaria da Saúde. Questionário de Suspeição de Hanseníase (QSH). Ribeirão Preto: Secretaria Municipal da Saúde de Ribeirão Preto; [sem data]. [citado em 08 jul. 2025]. Disponível em: https://www.ribeiraopreto.sp.gov.br/portal/pdf/saude2024202410.pdf.
8. Organização Pan-Americana da Saúde. Lepra/Hanseníase: gestão das reacções e prevenção das incapacidades. Orientações técnicas. Nova Delhi: Organização Mundial da Saúde, Escritório Regional para o Sudeste Asiático; 2020. [citado em 13 jul. 2025]. Disponível em: https://www.paho.org/pt/documentos/leprahanseniase-gestao-das-reaccoes-eprevencao-das-incapacidades-orientacoes-tecnicas.
9. Bernardes F Filho, Silva CML, Voltan G, Leite MN, Rezende ALRA, Paula NA de, et al. Active search strategies, clinicoimmunobiological determinants and training for implementation research confirm hidden endemic leprosy in inner São Paulo, Brazil. PLoS Negl Trop Dis. 2021;15(6):e0009495. doi: https://doi.org/10.1371/journal.pntd.0009495.
10. World Health Organization. Towards Zero Leprosy. Global Leprosy (Hansen’s disease) Strategy 2021-2030. New Delhi: World Health Organization, Regional Office for South-East Asia; 2017. [cited 2025 April 12]. Available from: https://www.who.int/publications/i/item/9789290228509.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Daphne Meyer Kahn, Melissa Thami Hirahara Miyasaki, Mariana Pinheiro Genari, Lucia Mioko Ito